Mike heads Cello Health’s Advanced Therapies and Rare Diseases practices. He also co-heads the oncology practice focusing on hematologic malignancies and genetically defined cancers.
He has 20 years’ experience in biotech ventures defining strategic development and early commercial strategy for academic and biotech inventions pertaining to nucleic acids, gene therapy and cellular platforms applied across monogenetic diseases and oncology.
Mike studied molecular pharmacology, cancer genetics and the role of recombinational DNA repair enzymes such as RAD51 paralogs at Thomas Jefferson University’s Kimmel Cancer Institute. His thesis research led to pioneering gene editing technologies which served the basis of several gene therapy, diagnostics, and agribiotechnology firms. Mike holds an MBA, with a concentration in Biotechnology, from the Alfred Lerner School of Business and Economics, at the University of Delaware
Mike is a member of the American Society of Gene and Cell Therapy (ASGCT), the Alliance for Regenerative Medicine (ARM), the Society for Immunotherapy of Cancer (SITC), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the Licensing Executives Society (LES), and the American Heart Association (AHA)
The World Advanced Therapies and Regenerative Medicine Congress and Exhibition is an international conference and exhibition featuring the latest in advanced therapies, bioengineering and surrounding technology. To attend the conference which features global leaders in the biopharma and regenerative medicine industries, there is a registration fee. The exhibition is free to visit.